Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: EnanDIM - a novel family of L-nucleotide-protected TLR9 agonists for cancer immunotherapy

Fig. 2

Immunological activation profile of EnanDIM-C (a-c), EnanDIM-A (d-f) and differences between both molecules (g, h). Human PBMC were treated without (black open squares) or with EnanDIM molecules (blue filled squares) at a final concentration of 3 μM for 48 h. Cytokines/chemokines were measured in cell culture supernatants (a n = 14–48, d n = 12–38, h n = 21) and activation of immune cells was analyzed by flow cytometry (b n = 13–29, c, e n = 12–34, f, g). Means are shown, differences between EnanDIM®-treated PBMC and controls were calculated using the paired t-test (*p < 0.05, **p < 0.01 ***p < 0.001) (a, b, d, e, h). Results from representative experiments are shown (c MFI of CD169 within monocytes is shown, f frequency of CD86 within B cells is shown, g HLA-DR expression of pDC)

Back to article page